Matinsista sanottua mm.
https://www.nature.com/articles/s41467-024-54295-x
" Bexmarilimab was well tolerated up to a dose of 10 mg/kg49 with no recordered dose-limiting toxicity. In spite of the low objective response-rate by RECIST criteria, there was promising disease control especially, in melanoma, but no responses in the ovarian cancer cohort50. The data we present here, suggest that the combination of Bexmarilimab with chemotherapy may lead to better response especially when the adaptive immune response is concomitantly targeted"